Free tool
FAERS Monitor: Kanjinti
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761073 or its brand name (Kanjinti, Trastuzumab-Anns). Reports on generic versions are filed under their own applications.
Reports
1,514
Serious
365
24% of reports
Hospitalization
111
Death reported
25
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product storage error346
- circumstance or information capable of leading to medication error257
- off label use115
- intercepted product administration error89
- product dose omission issue69
- diarrhoea64
- dyspnoea62
- chills58
- nausea54
- fatigue51
- rash49
- intercepted product preparation error42
- accidental exposure to product40
- product preparation error40
- infusion related reaction36
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2019 | 72 |
| 2020 | 217 |
| 2021 | 206 |
| 2022 | 248 |
| 2023 | 364 |
| 2024 | 278 |
| 2025 | 75 |
| 2026 | 53 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,645 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intercepted product administration errorSignal | 89 | 163.1 | 133.2 | 14,021 |
| circumstance or information capable of leading to medication errorSignal | 257 | 106.5 | 95.2 | 26,595 |
| product storage errorSignal | 346 | 55.1 | 50.2 | 18,336 |
| intercepted product preparation errorSignal | 42 | 47.6 | 35.3 | 1,863 |
| product preparation errorSignal | 40 | 27.1 | 20.0 | 979 |
| infusion related reactionSignal | 36 | 7.5 | 5.5 | 199 |
| chillsSignal | 58 | 6.9 | 5.3 | 287 |
| accidental exposure to productSignal | 40 | 5.4 | 4.0 | 139 |
| product dose omission issueSignal | 69 | 3.3 | 2.6 | 107 |
| off label use | 115 | 1.8 | 1.5 | 44 |
| rash | 49 | 1.6 | 1.2 | 10 |
| dyspnoea | 62 | 1.5 | 1.2 | 11 |
| diarrhoea | 64 | 1.4 | 1.1 | 6 |
| nausea | 54 | 0.9 | 0.7 | 0 |
| fatigue | 51 | 0.9 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.